The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index; none of the 200 sources its claims cite is checked for support yet.
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Open accessAbstract
Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that soluble Aβ oligomers, rather than insoluble amyloid plaques, are the primary synaptotoxic agents causing early memory failure in Alzheimer’s disease. It synthesizes cell, animal, and human evidence linking oligomers to synaptic plasticity disruption, synapse loss, tau pathology, insulin resistance, and candidate therapeutic strategies.
Key findings
- Aβ oligomers inhibit long-term potentiation (LTP) within minutes without affecting baseline excitability, and memory loss in APP transgenic mice can be reversed by anti-Aβ antibodies without removing amyloid plaques.
- Oligomers accumulate in AD-affected human brain and in essentially all transgenic AD models examined; synthetic and brain-derived oligomers show biochemical identity, and oligomer size remains debated (dimers–tetramers vs. 12mers/24mers), with SDS-stable 12mers linked to memory failure in one model.
- Oligomers target synapses: >90% co-localization with post-synaptic marker PSD-95; 50–85% of hippocampal neurons bind oligomers while others are spared; binding is associated with tau hyperphosphorylation, insulin receptor redistribution, spine loss, and oxidative stress.
- AD is discussed as a brain-specific form of diabetes (“type 3 diabetes”): Aβ oligomers induce insulin resistance, and intranasal insulin improves cognition in early AD at higher doses, consistent with insulin resistance.
Methods
- Narrative review of the literature, not a primary experimental study; it synthesizes findings from cell biology, animal models, human AD brain/CSF, and human genetics.
- Evidence discussed includes synthetic and brain-derived Aβ oligomers, transgenic mouse/rat/C. elegans/Drosophila models, electrophysiology (LTP/LTD), imaging, biochemical assays, and human clinical/ biomarker studies.
- Main analysis is qualitative synthesis; Tables 2 and 3 summarize synapse-specific and more generalized neuronal effects of Aβ oligomers.
Limitations
- Stated: the pathogenic oligomer size is uncertain; detection is limited by SDS-PAGE/Western blot, antibody choice, heat denaturation, and detergent; not all oligomers are toxic; nomenclature is confusing; why toxic oligomers accumulate in sporadic AD is largely unknown; intracellular vs. extracellular localization is unresolved; PrPC involvement is debated; synthetic oligomers can clump at high concentrations.
- Stated: published studies use different oligomer preparations, concentrations, incubation times, brain regions, and culture maturation stages, complicating comparison.
- Evident: as a narrative review, it lacks a systematic search strategy, formal quality appraisal, or meta-analysis, and presents an author-framed argument favoring the oligomer hypothesis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
132 Not checked yet · 46 Own interpretation · 15 No basis given · 1 Own method
In the paper
“A classic study by Terry, Masliah and colleagues subsequently confirmed that synapse loss is the best pathological correlate of Alzheimer’s dementia (Terry et al., 1991).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Terry et al., 1991 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Amyloid in fact is a poor correlate of disease state in AD models as in humans (Terry et al., 1991),”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Terry et al., 1991 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Dot immunoblots of soluble extracts from human brain show major increases in oligomers in AD-affected tissue (Gong et al., 2003; Kayed et al., 2003; Lambert et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Most importantly, these amyloid-free Aβ oligomers were potent CNS neurotoxins.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Its clinical relevance has been established by evidence that equivalent oligomers accumulate in AD-affected human brain and animal AD models.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
In the paper
“Mucke and colleague found that synapse loss does not require the presence of amyloid deposits (Mucke et al., 2000).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Mucke et al., 2000 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Recent findings by Bateman and colleagues show that clearance of Aβ in AD patients is reduced by 30% (Mawuenyega et al., 2010).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites Mawuenyega et al., 2010 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent evidence suggests that insulin resistance, a hallmark of diabetes, develops in Alzheimer’s brains (, 2000; Craft et al., 1999; de la Monte, 2009; Moroz et al., 2008; Pedersen and Flynn, 2004; Razay and Wilcock, 1994; Watson and Craft, 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In hippocampal slices, synthetic oligomers cause rapid LTP inhibition (Barghorn et al., 2005; Fa et al., 2010; Jurgensen et al., 2011; Lambert et al., 1998; Nimmrich et al., 2008; Rammes et al., 2011; Wang et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“At the cellular level, deficient insulin signaling results in impaired removal of Aβ (Plum et al., 2005) and Aβ oligomers from the extracellular milieu (Zhao et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 69
- Probably not a substantial claim. 20
In the paper
“Dodart, Paul and colleagues found that memory loss was reversed in APP tg-mice injected with antibodies against Aβ and that this reversal, moreover, did not require removal of amyloid plaques (Dodart et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
What the sources say
- Not checked yetcites Dodart et al., 2002 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Investigation into the action of clusterin by Lambert, Klein and colleagues established that, concomitant with inhibition of amyloid formation, clusterin promotes accumulation of soluble Aβ oligomers (Lambert et al., 1998).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“some neuropathologists rejected the hypothesis, emphasizing that a poor correlation exists between plaque load and cognitive function (Terry et al., 1994).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
What the sources say
- Not checked yetcites Terry et al., 1994
plaincorrelational- Asserted: fails — The authors may not put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The authors may not put it forward as true.
In the paper
“With chronic exposure, neurons ultimately were killed. Death was selective for subpopulations of vulnerable neurons and was prevented by knockout of Fyn, a protein tyrosine kinase linked to NMDA receptor signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on a central role for impaired signaling, the oligomer hypothesis predicted that early memory loss should be reversible. This prediction was confirmed in the transgenic mouse experiments mentioned above (Dodart et al., 2002; Kotilinek et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“oligomers were found to inhibit functional synaptic plasticity (Lambert et al., 1998). Long-term potentiation (LTP) was inhibited within minutes. This rapid loss of LTP, measured in rat brain slices and in situ in mice, occurred without impact on baseline excitability, indicating impairment of signaling rather than degeneration.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
What the sources say
- Not checked yetcites Lambert et al., 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At present it is uncertain whether one class is more germane to pathogenesis than another.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Remarkably, at sub-nanomolar doses, the effect on LTP is reversed, and Aβ markedly enhances LTP. Discovered by Arancio and colleagues in a detailed analysis (Puzzo et al., 2008), enhancement occurs over a narrow range of concentrations and is associated with presynaptic activation of alpha7 nicotinic receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
- Not checked yetcites Puzzo et al., 2008 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“And in fact, not all oligomers are toxic, even those oligomers of a given size. Subtle conformation changes affect toxicity and immunoreactivity (Chromy et al., 2003; Pitt et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Traumatic brain injury also is associated with acutely elevated levels in CSF, with a positive correlation between oligomer levels and severity of sequelae (David Brody, MP Lambert, and WL Klein, unpublished).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites David Brody, MP Lambert, and WL Klein, unpublished
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In FAD, metabolic effects of mutations promote increased levels of total Aβ, or increased Aβ42 to Aβ40 ratio (Borchelt et al., 1996; Citron et al., 1992), conditions that favor oligomerization.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“More generalized neuronal impacts of Aβ oligomers (Table 3) include Ca2+ dyshomeostasis, oxidative stress and mitochondrial damage, proteasome inhibition, tau accumulation and hyperphosphorylation, impairment of fast axonal transport, ER stress, inhibition of the proteasome, cell cycle re-entry and, ultimately, cell death.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The discovery that memory failure in tg mice coincides with the appearance of SDS-stable 12mers is compelling in situ evidence that this species is pathogenic (Lesne et al., 2006).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Clinical relevance: build up of toxic oligomers in AD and AD animal models
What the sources say
- Not checked yetcites Lesne et al., 2006 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Relative levels of Aβ42 to Aβ40 appear to influence the mechanism of oligomerization, with higher levels of Aβ40 in normal individuals likely impeding formation of stable toxic oligomers (Giuffrida et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Why do toxic oligomers accumulate?
What the sources say
- Not checked yetcites Giuffrida et al., 2009 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Tg-mouse AD models manifest a spontaneous age-onset impairment of LTP (Gong et al., 2004) that presumably is linked to impaired performance in memory tests (Arendash et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neurological consequences: Oligomers impair synapse plasticity and learning
What the sources say
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Synapse-specific effects of Aβ oligomers (Table 2) include alterations in neurotransmitter (glutamate/D-serine) levels, down-regulation (due to abnormal trafficking or degradation) of plasticity-related receptors at the plasma membrane, altered plasticity (inhibition of long term potentiation and/or facilitation of long term depression), cytoskeletal abnormalities and synapse loss.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Memory loss, beginning early in the disease, was attributed to oligomer-induced disruption of synaptic plasticity, with later stages of dementia attributed to oligomer-induced cellular degeneration and death.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Amyloid and nerve cell death are not the primary disease-causing pathologies
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses.”
- Also stated in: § Abstract · plain
“We summarize here why attention has shifted away from amyloid plaques as the toxic agents of AD to the contemporary concept that memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
- Also stated in: § Abstract · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The conclusion that Aβ oligomers can be neurologically significant toxins, possibly the most important ones for AD, is now supported by more than a decade of further investigation, with over 1,000 papers addressing the oligomer hypothesis.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Memory loss is a disruption of synaptic plasticity: the oligomer hypothesis
boostedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it now appears the most pathogenically relevant Aβ-derived toxins are small soluble oligomers, not readily detected.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
In the paper
“The hypothesis attributed dementia to nerve cell death caused by the toxicity of large insoluble amyloid fibrils.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis
What the sources say
- Not checked yetcites Hardy and Higgins, 1992 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In conclusion, besides directly affecting memory-related processes, the various impacts of Aβ oligomers on neurons have the potential to account for major facets of AD neuropathology (e.g., tau hyperphosphorylation, oxidative stress, synapse loss), supporting the concept that Aβ oligomers provide a unifying mechanism for initiation of AD pathogenesis.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Synapse-specific and other pathological cellular consequences of ADDL binding to neurons
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Serine phosphorylation precludes tyrosine phosphorylation of IRS-1, blocking downstream insulin signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Physiologically, IRS-1 is phosphorylated at tyrosine residues by the tyrosine kinase activity of the IR, which activates downstream signaling in the insulin pathway (Araki et al., 1994; White, 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“IRs are present in the brain, where they are abundantly distributed in synaptic membranes of the cerebral cortex and hippocampus (Abbott et al., 1999; Havrankova et al., 1981; Marks et al., 1990; Unger and Betz, 1998).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Aβ oligomers induce a striking redistribution of IRs, causing their internalization from dendritic membranes and accumulation in the cell body. This renders neurons insulin resistant (De Felice et al., 2009; De Felice et al., 2008; Zhao et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Brain insulin signaling declines with age (Frolich et al., 1998; , 1999; Hoyer, 1998; Rivera et al., 2005), the primary risk factor for AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“an elevated risk for AD also exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling (Matsuzaki et al., 2010; Ott et al., 1999; Toro et al., 2009; Watson and Craft, 2003), likely as a consequence of decreased insulin uptake into the brain following sustained peripheral hyperinsulinemia (Gerozissis et al., 1993; Kaiyala et al., 2000; Schwartz et al., 1990).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Internalization occurs by a mechanism mediated by casein kinase 2 (CK2) and Ca2+/calmodulin-dependent kinase 2 (CaMK II), which also are involved in ADDL-induced internalization of NMDA receptors (De Felice et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites De Felice et al., 2009 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
- Not checked yetcites Lacor et al., 2004 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, physiological insulin signaling may play an important role in defending neurons against AD, suggesting the loss of CNS insulin signaling in aging and diabetes is a potential risk factor for AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“When given to subjects with early AD, intranasal insulin also improves performance (Reger et al., 2008b) but only at higher doses, consistent with expected insulin resistance and suggesting possible involvement of additional mechanisms other than stimulation of plasticity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites Reger et al., 2008b
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Aβ oligomers induce a marked removal of IRs from synapses, decreasing the responsiveness of nerve cells to insulin.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The insulin-sensitizing drug rosiglitazone, a PPAR-γ agonist, potentiates the ability of insulin to protect synapses against Aβ oligomers, while a cell-permeant inhibitor of the tyrosine kinase activity of the IR abrogates the protection by insulin.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of IRs and synapse loss (De Felice et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
- Not checked yetcites De Felice et al., 2009 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the ability of antibodies to reverse intracellular tau and synapse pathology (Chauhan et al., 2008; Oddo et al., 2006) and to provide cognitive benefits (Hillen et al., 2010; Takamura et al., 2011).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“stimulation of insulin signaling also protects against accumulation of hyperphosphorylated tau (Escribano et al., 2010), a pathological hallmark of AD that is induced by Aβ oligomers (De Felice et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The mechanism of protection does not involve direct competition between Aβ oligomers and insulin for a common binding site on the neuronal surface. Rather, it consists of an IR signaling-dependent down-regulation of neuronal ADDL binding sites.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Neuronal insulin resistance induced by Aβ oligomers: AD as a novel form of brain-specific diabetes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clustering of oligomers at synapses, moreover, shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies. AD type tau hyperphosphorylation (De Felice et al., 2008), redistribution of insulin receptors (De Felice et al., 2009; Zhao et al., 2008), spine loss (Lacor et al., 2007) and oxidative stress (De Felice et al., 2007; Decker et al., 2010a) are manifest exclusively in”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
What the sources say
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, the peri-somatic distribution in human brain is evident in the complete absence of amyloid plaques, indicating oligomer pathology occurs early in the disease process.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As expected, the pattern of binding depends on cell maturation.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These oligomer-targeted neurons are distributed sparsely, indicating oligomers might originate within the cells they surround (Figure 1, right).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It can be concluded that oligomers are gain-of-function pathogenic ligands that target and disrupt signaling at particular synapses, a specificity that may explain why early AD is a disease of memory.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Lauren et al., 2009 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Significantly, some neurons are targeted while others are not, establishing clear-cut specificity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Initiating mechanisms – the targets are synapses
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“EphB2 receptors interact functionally and physically with NMDARs at synapses”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other putative receptors/co-receptors involved in neuronal binding of Aβ oligomers include the p75 neurotrophin receptor (p75NTR) (Knowles et al., 2009), the receptor for advanced glycation end products (RAGE) (Sturchler et al., 2008), nicotinic acetylcholine receptors (Magdesian et al., 2005) and Frizzled (Magdesian et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggest that ADDL binding to synapses may involve the assembly of a multi-protein receptor whose assembly is promoted by NMDARs and likely involves other participants, including PrPC.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These observations indicate that NMDARs are necessary but not sufficient for ADDL binding”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This suggests that initial ADDL binding recruits more PrPC molecules (presumably by exocytosis of vesicles located proximal to the plasma membrane; (Caetano et al., 2011)) to form a higher order complex that may initiate toxic signaling at”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Caetano et al., 2011 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“NMDARs co-immunoprecipitate with Aβ oligomers from detergent-extracted oligomer-treated rat synaptosomal membranes, and an N-terminal anti-NR1 antibody markedly reduced oligomer binding to dendrites (De Felice et al., 2007).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites De Felice et al., 2007 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NMDAR knock-down also abrogates neuronal oxidative stress induced by Aβ oligomers, which is mediated by aberrant activation of NMDARs (De Felice et al., 2007).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites De Felice et al., 2007 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A second prediction based on altered Arc expression is that oligomers would induce aberrant dendritic spine morphology, and this also has been confirmed in culture and in situ (Lacor et al., 2007; Ma et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Lacor et al., 2007 source
- Not checked yetcites Ma et al., 2009
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although receptors are lost from the surface, total levels are at first unchanged, indicating dysfunctional trafficking”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“What emerges from current evidence is that Aβ oligomers first bind to the neuronal plasma membrane at freely moving receptors, but lateral diffusion leads to interactions between Aβ oligomers and membrane proteins such as mGluR5 that ultimately target Aβ oligomers to synaptic sites.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Initially, Aβ oligomers diffused as if bound to an untethered protein. Within minutes, however, movement slowed and oligomers became immobilized, typically at active synapses labeled with FM4-64. The synaptic trapping of oligomers was accompanied by co-clustering and immobilization of mGluR5 metabotropic glutamate receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Renner et al., 2010 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Within minutes of exposure to oligomers, neurons show a localized over-expression of Arc, which later spreads ectopically throughout the dendrite.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Arc is an immediate early gene product that is translated from mRNA in dendritic spines (Bramham, 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Bramham, 2008 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The mechanism of oligomer synapto-toxicity appears to be tied closely to accumulation of excessive levels of Ca++ (Marx, 2007), consistent with involvement of NMDA and mGluR5 receptors.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Marx, 2007 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interaction with Aβ oligomers could potentially dysregulate such signaling pathways, resulting in neurotoxicity.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“PrPC has been proposed to act as a cell-surface platform that orchestrates several physiological signaling pathways at the neuronal plasma membrane (for reviews, see (Linden et al., 2008; Martins et al., 2010)).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > How spines are targeted by Aβ oligomers – receptors, co-receptors, scaffolds and toxic clusters
What the sources say
- Not checked yetcites Linden et al., 2008 source
- Not checked yetcites Martins et al., 2010
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The consequent chronic mGluR5 activity would keep FMRP dephosphorylated and eliminate the ability of FMRP to repress mRNA translation.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Such aberrant spines also are seen in traumatic brain injury and prionoses (Fiala et al., 2002).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Fiala et al., 2002 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Fragile X also leads to hyperactivity in the protein phosphatase PP2a (Kim et al., 2008) which inactivates MAPK, an enzyme with impaired activity in oligomer-exposed neurons (Tong et al., 2001).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hyperactivity of mGluR5 receptors caused by oligomers is due to a clustering mechanism, as described earlier, and this receptor state hypothetically could be insensitive to negative feedback by FMRP.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Spines after short-term exposure to oligomers are long and spindly, resembling immature spines that express low levels of AMPA-Rs, as found early in development.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In the absence of FMRP, mGluR5 is hyperactive, with the consequences detailed above, and mGluR5 antagonists have been suggested as an approach to Fragile X treatment.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“This mechanism is in many respects analogous to the clustering of receptors at immunological synapses during T cell activation (Douglass and Vale, 2005), with the fundamental difference that oligomer-induced clustering is toxic.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Douglass and Vale, 2005
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Its control of Arc is a prime example (Iacoangeli et al., 2008).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
- Not checked yetcites Iacoangeli et al., 2008 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Eventually, spines deteriorate and synapses are lost, consistent with low levels of Arc found in mature tg-mice (Chin et al., 2005).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
- Not checked yetcites Chin et al., 2005 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additional synaptic pathologies instigated by oligomers also are present in Fragile X, including aberrant spine morphology, loss of NMDA and AMPA receptors, and elevated LTD (Bear et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
- Not checked yetcites Bear et al., 2004 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Fragile X is a developmental disorder caused by inability to express the regulatory protein FMRP.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Another actin binding protein found in spines, drebrin, also becomes greatly diminished in culture (Lacor et al., 2007) and in tg-mice (Calon et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Clustering can be elicited by mGluR5 antibodies, and antibody-induced clustering mimics the effects of oligomers in causing elevated Ca++ and synapse deterioration.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Oligomer-induced Ca++ elevation: Consequences and a novel triggering mechanism
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“there is also reason to believe that non-pharmacological approaches based on these novel findings might be beneficial to ameliorate AD symptoms (Schaeffer et al., 2009).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
- Not checked yetcites Schaeffer et al., 2009 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For example, exercise and a balanced diet might have positive effects on both peripheral and brain insulin signaling.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One of the implications of this finding is that D1/D5 receptors may constitute a target for the development of novel approaches to combat synapse failure in AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In particular, the discovery that insulin resistance plays an important role in the pathogenesis of AD suggests that strategies aimed to bolster brain insulin signaling might be beneficial in preventing synapse failure and neuronal damage in AD.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“dopaminergic neurotransmission, centrally implicated in the brain reward system and known to decline with aging (De Keyser et al., 1990), plays important roles in non-pharmacological strategies aimed to improve age-related cognitive decline, such as environmental enrichment and physical exercise (van Praag et al., 2000).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Oligomer-induced hyperactivity of mGluR5 in Alzheimer’s disease would thus promote production of even more Aβ and oligomers.”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Comparison with another disorder of learning and memory: AD and Fragile X Syndrome show striking similarities
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“a connection has recently been established between dopaminergic signaling and AD, with demonstration that selective activation of D1/D5 dopamine receptors prevents pathological changes in synapse composition and function (including inhibition of LTP) induced by Aβ oligomers (Jurgensen et al., 2011).”
§ The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's diseas > The original amyloid cascade hypothesis > Promise of therapeutics
What the sources say
- Not checked yetcites Jurgensen et al., 2011 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.
“the symptom that first brings patients to a physician is a troubling inability to form new memories, and early AD is largely regarded as a disease of memory formation.”
The paper relies on this without support.
AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.
“This article reviews progress in the search for primary AD-causing toxins.”
“If we could regard AD as having a single disease-initiating cytotoxin (albeit one likely elicited by multiple factors), its action minimally must provide a basis for memory dysfunction.”
The authors state this as an assumption.
Aβ oligomers act from the extracellular milieu.
“A premise for investigating the effects of exogenous oligomers on memory and neuropathology is that oligomers presumably act from the extracellular milieu.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, the production of Aβ is a complex process and accumulating evidence indicates that soluble Aβ oligomers, not Aβ plaques alone, are the disease-causing species that induce substantial neurotoxicity including synaptic dysfunction and behavioral impairment [see review in Ref. (138)].”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [138]
In the citing paper
“In vivo and in vitro studies support a direct relationship between OS and synaptic dysfunction in AD [18,86,87,88,89,90].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [88]
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPratchayasakul, W., Kerdphoo, S., Petsophonsakul, P., Pongchaidecha, A., Chattipakorn, N., & Chattipakorn, S. C. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.02.003 · Cited by 206
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Cited by
Sorted by citations
Items 301–400 of 442
Salimi, A., Li, H., & Lee, J. Y. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.06.078 · Cited by 14
Kaur, P., Kibat, C., Teo, E., Gruber, J., Mathuru, A. S., & Tolwinski, N. S. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3856 · Cited by 12
Preetham, H. D., Umashankara, M., Kumar, K. S. S., Rangappa, S., & Rangappa, K. S. (2022) · Journal of Peptide Science · doi:10.1002/psc.3386 · Cited by 12
Paula-Lima, A. C., & Hidalgo, C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00120 · Cited by 12
“These toxic effects presumably underlie the loss of neuronal connectivity characteristic of AD (Ferreira and Klein, 2011).”
BackgroundIncreased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice
Salas, I. H., Callaerts-Vegh, Z., D’Hooge, R., Saido, T. C., Dotti, C. G., & De Strooper, B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180410 · Cited by 12
Research Mechanism and Progress of the Natural Compound Curcumin in Treating Alzheimer’s Disease
Li, L., Wang, F., Jia, X., Yao, L., & Liu, Y. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575263783231009051957 · Cited by 11
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 14
“The oligomeric forms can alter neurotransmitter uptake/release, synaptic plasticity, and cellular receptor localization, as well as cause memory deficits in animal models [94–96].”
Li, X., Qiu, Y., Zhou, J. H., & Xie, Z. (2021) · Current Genomics · doi:10.2174/1389202923666211216163049 · Cited by 11
Ontology Specific Alternative Splicing Changes in Alzheimer’s Disease
Lu, Y., Yue, D., Xie, J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.926049 · Cited by 11
“The neuropathology of AD includes extracellular β-amyloid deposition and neurofibrillary tangles formed by hyperphosphorylated tau (Ferreira and Klein, 2011).”
BackgroundSafari, S., Mirazi, N., Ahmadi, N., Asadbegi, M., Nourian, A., Ghaderi, S., Rashno, M., & Komaki, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03225-x · Cited by 12
“Aβ aggregation may be associated with impaired hippocampal synaptic plasticity and reduced cognitive ability in AD [20, 21].”
BackgroundCerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
Rådestig, M. A., Skoog, I. G., Skillbäck, T. B., Zetterberg, H., Kern, J., Zettergren, A., Andréasson, U., Wetterberg, H., Kern, S., & Blennow, K. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01193-x · Cited by 11
“Oligomers can also affect other events important in AD pathology such as oxidative stress, neuroinflammation hyperphosphorylation of tau, and synaptic or neuronal death [40, 46, 47].”
BackgroundAlzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis
Whitfield, J. F., Rennie, K., & Chakravarthy, B. (2023) · Cells · doi:10.3390/cells12121618 · Cited by 11
Do age and sex impact on the absolute cell numbers of human brain regions?
de Oliveira-Pinto, A. V., Andrade-Moraes, C. H., Oliveira, L. M., Rayêe, D., Santos, R. M., Coutinho, R., Alho, A. T. D. L., Leite, R. E. P., Suemoto, C. K., Grinberg, L. T., et al. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1118-4 · Cited by 11
“…for men (blue), and women (red) memory deficits of aging, now attributed to the subcellular, molecular action of b-amyloid oligomers on dendrites (Cochran et al. 2014) and synapses (Ferreira and Klein 2011), and of hyperphosphorilation of tau-protein on neuronal physiology (Flunkert et al. 2013).”
BackgroundSanMartín, C. D., Paula-Lima, A. C., Hidalgo, C., & Núñez, M. T. (2012) · BioMetals · doi:10.1007/s10534-012-9545-7 · Cited by 11
“Accumulation of the amyloid beta (Ab) peptide in the brain correlates directly with AD pathogenesis (Ferreira and Klein 2011; Glenner and Wong 1984; Masters et al. 1985).”
Epistasis analysis links immune cascades and cerebral amyloidosis
Initiative, A. D. N., Benedet, A. L., Labbe, A., Lemay, P., Zimmer, E. R., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Mohades, S., Shin, M., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0436-z · Cited by 13
Mhillaj, E., Cuomo, V., & Mancuso, C. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000296 · Cited by 11
“…2013), inhibition of longterm potentiation (LTP) (Walsh et al., 2002), alteration of glutamatergic synapses (Shankar et al., 2007; Green and LaFerla, 2008; Canas et al., 2014) and cognitive impairment (Ferreira and Klein, 2011; ; Morgese et al., 2014; Tucci et al., 2014; Balducci et al., 2017).”
BackgroundSingh, R. J., Joshi, A., Koundal, M., Sabharwal, A., Verma, N., Gahalot, D., & Sunkaria, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.050 · Cited by 11
β-amyloid’s neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review
O'connell, A., Quinlan, L. R., & Kwakowsky, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107436 · Cited by 12
Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective
Pal, C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167617 · Cited by 12
Shobo, A., Röntgen, A., Hancock, M. A., & Multhaup, G. (2022) · FEBS Letters · doi:10.1002/1873-3468.14358 · Cited by 9
Effects of Terahertz Radiation on the Aggregation of Alzheimer’s Aβ42 Peptide
Wang, L., Cheng, Y., Wang, W., Zhao, J., Wang, Y., Zhang, X., Wang, M., Shan, T., & He, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055039 · Cited by 10
Wnt Signaling Rescues Amyloid Beta-Induced Gut Stem Cell Loss
Kaur, P., Chua, E. H. Z., Lim, W. K., Liu, J., Harmston, N., & Tolwinski, N. S. (2022) · Cells · doi:10.3390/cells11020281 · Cited by 10
Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers
Tan, W., Thiruppathi, J., Hong, S. H., Puth, S., Pheng, S., Mun, B.-R., Choi, W., Lee, K., Park, H., Nguyen, D. T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00904-1 · Cited by 10
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Pires, E. N. S., Ferreira, S. T., & Linden, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15129 · Cited by 9
“The numbers of animals required for each experiment were estimated based on previous experience of the authors with the impact both of OGD and of Aβ oligomers on synaptic proteins (e.g. Simões Pires et al., 2014; Ramírez-Sánchez et al., 2015; De Felice, 2007; Ferreira & Klein, 2011).”
BackgroundMethodSelf-citationTraumatic Brain Injury and Alzheimer’s Disease: A Shared Neurovascular Hypothesis
Cognacq, G., Attwood, J. E., & DeLuca, G. C. (2025) · Neuroscience Insights · doi:10.1177/26331055251323292 · Cited by 9
Sulforaphane Upregulates Cultured Mouse Astrocytic Aquaporin-4 Expression through p38 MAPK Pathway
Yang, C., Qin, S., Zhang, J., Wang, Y., Li, H., & Lü, T. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/1144124 · Cited by 8
Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer’s Disease
Cho, H. J., Schulz, P., Venkataraman, L., Caselli, R. J., & Sierks, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415670 · Cited by 6
“AD is a progressive neurodegenerative disorder [43,44] associated with the generation of protein variants of Aβ, tau, and TDP-43 [13,34,45–49].”
BackgroundSafari, S., Mirazi, N., Ahmadi, N., Asadbegi, M., Nourian, A., Rashno, M., & Komaki, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06317-7 · Cited by 10
“2005; Ferreira and Klein 2011).”
Allnutt, M. A., & Matera, K. M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04036-1 · Cited by 9
Ribeiro, F. C., Cozachenco, D., Parkhill, M., Rodrigue, B., Borges, C., Lacaille, J., Nader, K., Felice, F. G. D., Lourenco, M. V., Aguilar‐Valles, A., et al. (2025) · Aging Cell · doi:10.1111/acel.70315 · Cited by 8
Self-citationTian, X., Wang, Y., Zhou, Y., Wu, B. Y., Lu, Y., Du, J., Wang, W., Cai, W., & Xiao, Y. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000536 · Cited by 9
Acun, A. D., Kantar, D., Er, H., Erkan, O., Derin, N., & Yargıçoğlu, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03334-7 · Cited by 8
Introduction and Technical Survey: Protein Aggregation and Fibrillogenesis
Harris, J. R., & Milton, N. G. N. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_1 · Cited by 8
Banerjee, A., Paluh, J. L., Mukherjee, A., Kumar, K. G., Ghosh, A., & Naskar, M. K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152664 · Cited by 8
Developing BACE-1 inhibitors for FXS
Westmark, C. J., Berry‐Kravis, E., Ikonomidou, C., Yin, J. C. P., & Puglielli, L. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00077 · Cited by 8
“Together these studies suggest a positive feedback loop whereby Aβ oligomers facilitate mGluR5 signaling leading to increased dendritic APP translation, which provides more target for amyloidogenic processing and the generation of additional Aβ (Ferreira and Klein, 2011; Westmark, 2013).”
BackgroundTauopathies: Emerging discoveries on tau protein, with a special focus on Alzheimer's disease
Hattiholi, A., Hegde, H., & Shetty, S. K. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102536 · Cited by 11
Fazelinejad, H., Zahedi, E., Nazarian, S., Siuki, Z. K., Nasri, S., Dadmehr, M., Mehrabi, M., & Khodarahmi, R. (2022) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-022-02692-8 · Cited by 7
Aquaporin-4 Mediated Aggregation of Alzheimer’s Amyloid β-Peptide
Maroli, N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00233 · Cited by 7
Hsieh, S., Liu, M., Huang, L., Wu, M., & Yang, Y. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200103114550 · Cited by 7
Imaging organelle transport in primary hippocampal neurons treated with amyloid-β oligomers
Gan, K. J., & Silverman, M. A. (2015) · Methods in cell biology · doi:10.1016/bs.mcb.2015.06.012 · Cited by 7
Brünner, Y. F., Benedict, C., & Freiherr, J. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3806-8 · Cited by 6
Establishment of a Drosophila AD model
Wang, X., Zhao, Y., Hu, Y., et al. (2016) · Journal of Biological Methods · doi:10.14440/jbm.2016.61 · Cited by 6
“Though the extracellular senile plaques (SP) containing the Aβ peptides have been proposed as a major cause of AD [10-12], the pathological role of Aβ peptides in AD progression has been challenged.”
BackgroundNam, S. (2017) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21095 · Cited by 6
Almeida, D. S., Brígido, M. M., Anjos, M. J., Ferreira, S. T., de Souza, A. S., & Lopes, R. T. (2019) · X-Ray Spectrometry · doi:10.1002/xrs.3044 · Cited by 7
Self-citationŞimşek, H., & Uçar, A. (2022) · Advances in Gerontology · doi:10.1134/s2079057022020175 · Cited by 6
The role of Aβ in Alzheimer's Disease as an Evolutionary Outcome of Optimized Innate Immune Defense
Tatar, M. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.68 · Cited by 6
“The oligomers of Aβ are considered to be toxic (72).”
BackgroundZhen, R.-R., Qu, Y.-J., Zhang, L.-M., et al. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01137-8 · Cited by 5
“2016; Ferreira and Klein 2011).”
Wang, K., Na, L., & Duan, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200916123000 · Cited by 5
Ye, S., Zeng, R., Jiang, P., Hou, M., Liu, F., Wang, Z., Du, X., Yuan, J., Chen, Y., Cao, H., et al. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.02.024 · Cited by 6
Innate Immune Tolerance Regulates Microglia Response to Aβ Oligomers
Valerio, R. R., Santos, Á. R., Nóbrega, A. H. L., Martins, R., Felice, F. G. D., Ferreira, S. T., Savino, W., Bonomo, A. C., Bernardi, A., & Frozza, R. L. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70341 · Cited by 5
“In the current study, we evaluated the development of innate immune tolerance in microglia and its influence on the subsequent inflammatory response caused by AβOs, proximal neurotoxins involved in AD (Ferreira and Klein 2011; Frisoni et al. 2022).”
Self-citationHou, Z., Song, Y., Liu, A., Sun, L., Gao, C., Cai, X., Xie, Y., Chen, T., Wu, A., & Lin, J. (2026) · Thermochimica Acta · doi:10.1016/j.tca.2026.180223 · Cited by 4
da Silva, A. F., Gomes, A., Gonçalves, L., Fernandes, A. M. A., & Almeida, A. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020141 · Cited by 4
Trumbore, C. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171080 · Cited by 4
Williams, E., Mutlu-Smith, M., Alex, A., Chin, X. W., Spires‐Jones, T. L., & Wang, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221185 · Cited by 5
Findley, C. A., McFadden, S., Hill, T., Peck, M. R., Quinn, K., Hascup, K. N., & Hascup, E. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240795 · Cited by 3
Javaid, M. A., Selim, M. H., Ortega‐Gutiérrez, S., Lattanzi, S., Zargar, S., Alaouieh, D., Hong, E., & Divani, A. A. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106489 · Cited by 4
Inhibition of β-amyloid Aggregation of Ugni molinae Extracts
Jara-Moreno, D., Riveros, A. L., Barriga, A., Kogan, M. J., & Delporte, C. L. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200113160840 · Cited by 4
Yu, D., Wang, L., Kong, D., & Hongtu Zhu, B. (2020) · arXiv (Cornell University) · Cited by 3
Katsoti, V., Ofrydopoulou, A., & Τσούπρας, Α. (2025) · Sclerosis · doi:10.3390/sclerosis3040033 · Cited by 3
Sex differences in sleep fragmentation in 5xFAD mice
Kim, K., Villegas, A.-R., Kelley, A., Labut, E. M., Hagen, T. M., Magnusson, K. R., & Kloefkorn, H. E. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.035 · Cited by 3
Nigdelioglu, E., Toprak, E., Güney, M., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137628 · Cited by 3
Hupert, M., Elfgen, A., Schartmann, E., et al. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.12.009 · Cited by 3
Tarif, A. M. M., Huhe, H., & Ohno, M. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06525-9 · Cited by 3
“Anyway, combination treatment did not further lower the levels of these molecules including Aβ oligomers, which are proposed to cause AD-related synaptic and cognitive deficits (Haass and Selkoe 2007; Ferreira and Klein 2011; Larson and Lesné 2012).”
Depression, Diabetes and Dementia
Rosenblat, J. D., Mansur, R. B., Cha, D. S., Baskaran, A., & McIntyre, R. S. (2014) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000365529 · Cited by 3
Effects of Bioactive Components of Green Tea on Alzheimer's Disease
Ide, K., Kawasaki, Y., Kawakami, K., & Yamada, H. (2018) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64058-1.00005-4 · Cited by 3
Neurodegenerative Diseases as Protein Folding Disorders
Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3
Ahmadi, A., Roghani, M., Noori, S. K., & Nahri-Niknafs, B. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180716122608 · Cited by 3
Determining the effects of nanoparticulate air pollution on proteostasis in Caenorhabditis elegans
Green, E. H., & Kikis, E. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243419 · Cited by 3
USP 46: a new piece of the memory puzzle?
Ribeiro, F. C., Santos, L. E., & Ferreira, S. T. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13227 · Cited by 3
Self-citationHsien, L. C., Kaur, P., Teo, E., Lam, V. Y. M., Zhu, F., Kibat, C., Mathuru, A. S., Gruber, J., & Tolwinski, N. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/836593 · Cited by 3
Colettis, N. C., Oberholzer, M. V., Cercato, M. C., Habif, M., Sellés, M. C., Salas, D. A., Sebollela, A. S., Klein, W. L., Epstein, A. L., Salvetti, A., et al. (2023) · Journal of Applied Cognitive Neuroscience · doi:10.17981/jacn.4.1.2023.2 · Cited by 3
Self-citationByeon, G., Kim, S., Kim, S., Um, Y. H., Wang, S., Ha, S., Park, S. Y., Choe, Y. S., Kim, D., Lim, H. K., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100318 · Cited by 3
“Among these, soluble oligomerized A β (OA β ) has been identified as the most neurotoxic species, primarily due to its ability to disrupt synaptic function, induce neuroinflammation, and impair neuronal viability even in the absence of plaque formation [13].”
Mathew, J., Maroky, A. S., SINDURAJ, S., & Chandrababu, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i5.54564 · Cited by 3
Almeida, D. S., dos Santos, R. S., Anjos, M. J., Ferreira, S. T., de Souza, A. S., & Lopes, R. T. (2017) · X-Ray Spectrometry · doi:10.1002/xrs.2753 · Cited by 2
Self-citationALZHEIMER HASTALIĞI, RİSK FAKTÖRLERİ VE TEDAVİ
Yıldırım, N., & Eke, B. C. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1441827 · Cited by 4
Cha, M., Kim, S.-M., Jung, E., Cho, I., Park, I., Yoon, S., Ye, S., Lee, S., Kim, J., Kim, H. Y., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00068 · Cited by 2
Aziz, N., Wal, P., Singh, Y. K., Kumar, P., & Singh, B. (2024) · Current Drug Therapy · doi:10.2174/0115748855299317241014051505 · Cited by 2
Mechanisms of the Pathogenesis of Alzheimer’s Disease: The Role of the Basal Forebrain
Kitchigina, V. F., Popova, I. Y., & Shubina, L. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01784-1 · Cited by 2
“…42o can interact with the α 7-con-taining nicotinic receptor ( α 7 2-nAChR) to cause hyperex-citation of neurons, which may be responsible for their neurotoxicity [Lambert et al., 1998; Ferreira and Klein, 2011; Selkoe, 2012; Mucke and Selkoe, 2012; Yang et al., 2017; George et al., 2021] (see Fig.”
Mitochondrial quality control by mitochondrial ubiquitin ligase MITOL/MARCH5
Nagashima, S., Takada, T., & Yanagi, S. (2017) · Folia Pharmacologica Japonica · doi:10.1254/fpj.149.254 · Cited by 2
Biomarkers of Alzheimer’s disease
Pitt, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00048-8 · Cited by 2
Topological Biomarker of Alzheimer’s Disease
Golubić, S. J. (2018) · InTech eBooks · doi:10.5772/intechopen.76633 · Cited by 2
“Consequently, failure of amyloid-based AD treatments shifts research hypothesis to the soluble amyloid beta oligomers rather than plaques to be the main cause of neuronal degeneration [16].”
BackgroundSiqueira, L. D., Celes, A. P. M., dos Santos, H., & Ferreira, S. T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210139 · Cited by 2
Self-citationThe New Products from Brown Seaweeds: Fucoxanthin and Phlorotannins
Yan, X., Zhang, J., He, S., Cui, W., & Gao, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-92174-3_9 · Cited by 2
Binding mechanism of full-length Aβ40 peptide to a mixed lipid bilayer
Wang, K., & Cai, W. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1367793 · Cited by 2
Alaziqi, B. H., Beckitt, L., Townsend, D. J., Morgan, J., Price, R., Maerivoet, A., Madine, J., Rochester, D. L., Akien, G. R., & Middleton, D. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c01281 · Cited by 4
Role of ROS in Aβ42 mediated cell surface P-selectin expression and actin polymerization
Tsoy, A., Askarova, S., Shalakhmetova, T. M., Umbayev, B. A., Adambekov, S., & Zhumadilov, Z. S. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-s1-p44 · Cited by 2
Nagahama, T., Nakajima, H., Wakuta, M., Kasahara, Y., Narita, K., & Nagahama, S. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.06.004 · Cited by 1
“o-Aβ induces signaling impairment via synaptic dysfunction in the early stages of AD and via the degeneration of neurons in the later stages (Ferreira and Klein, 2011).”
Sensitive Detection of Amyloid Beta 42 Using NiO Based Electrochemical Immunosensor
Singh, J. P., Bali, N. B., Chowdhuri, A., Naorem, A., Verma, M., Tomar, M., Singh, N., & Naorem, B. D. (2025) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/addaea · Cited by 1
Qin, H. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/fqnpvn24 · Cited by 1
Perakis, E., & Vlamos, P. (2025) · Mathematics · doi:10.3390/math13223724 · Cited by 1
Batista, A. F., Presumey, J., Singh, B. B., Yalçın, E., Schroeder, M. K., Khan, K., Spooner, E., Li, S. A., Carroll, M. C., & Lemere, C. A. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00010-z · Cited by 3
Shimizu, K., Yasuda, S., Maeshima, H., Ichikawa, T., & Baba, H. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70109 · Cited by 1
Mutations remodel interaction networks in mixed Aβ(14–23) oligomers: a molecular dynamics study
Zein, H. F. (2026) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2026.115852 · Cited by 1
Hurley, D. (2012) · Neurology Today · doi:10.1097/01.nt.0000410755.19813.06 · Cited by 1
Frontiers in Clinical Drug Research - Alzheimer Disorders
Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1
Von der Nase ins Gehirn: Effekte intranasal verabreichten Insulins
Brünner, Y. F., Benedict, C., & Freiherr, J. (2013) · Der Nervenarzt · Cited by 1
Curcumin against amyloid pathology in mental health and brain composition
Tooyama, I., Ibrahim, N. F., Durani, L. W., Hamezah, H. S., Damanhuri, M. H. A., Ngah, W. Z. W., Taguchi, H., & Yanagisawa, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802972-5.00023-8 · Cited by 2
ER Stress Signaling in Alzheimer's Disease
Rahman, M. M., Shrestha, L., & Gulshan, M. A. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch007 · Cited by 1
Beckman, D., Donis‐Cox, K., Ott, S. P., Roberts, M. A., Novik, L., Janssen, W. G. M., Bliss‐Moreau, E., Rudebeck, P. H., Baxter, M. G., & Morrison, J. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/251025 · Cited by 1
Metadata
- Authors
- Ferreira, S. T., & Klein, W. L.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Northwestern University (US)
- Corresponding author
- Klein, William L.
- Venue
- Neurobiology of Learning and Memory
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 96
- Issue
- 4
- Pages
- 529-543
- ISSN
- 1074-7427 (ISSN-L)
- PMC
- PMC4390395
- OpenAlex
- W2051268743
- Cited by
- 442
- References
- 286
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 22 · 2023: 24 · 2022: 37 · 2021: 28 · 2020: 35 · 2019: 23 · 2018: 44 · 2017: 41 · 2016: 33 · 2015: 35 · 2014: 38 · 2013: 24 · 2012: 26
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Learning and Memory (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG022547, R01AG029460, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, memory loss, amyloid plaques, pathogenesis, diabetes mellitus, fragile X syndrome, animal models of Alzheimer's disease, Alzheimer's disease treatment
- MeSH terms
- Alzheimer Disease, Brain, Humans, Memory Disorders, Neurons, Synapses, Amyloid beta-Peptides, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
